Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand Expects First Of Two Osteoporosis SERM Launches As Early As 2002

Executive Summary

Ligand collaborator Pfizer could launch the first of the company's selective estrogen receptor modulators for osteoporosis as early as 2002, the company told analysts March 20.
Advertisement

Related Content

Wyeth SERM ERA-923 In Phase II For Tamoxifen-Refractory Patients
Wyeth SERM ERA-923 In Phase II For Tamoxifen-Refractory Patients
Targretin Is Second Product In Ligand CTCL Therapy Triple Offering
Advertisement
UsernamePublicRestriction

Register

PS037557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel